Nexgel (NXGLW) EBITDA (2018 - 2026)

Nexgel (NXGLW) has reported EBITDA for 9 consecutive years, with -$2.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA fell 293.87% year-over-year to -$2.5 million; the trailing twelve-month figure through Jun 2026 stood at -$5.1 million (down 67.0% YoY), and the FY2025 full-year result was -$3.4 million, up 5.68% from the prior year.
• EBITDA eased to -$2.5 million in Q2 2026 per NXGLW's latest filing, from -$1.2 million in the prior quarter.
• Across five years, EBITDA topped out at -$612000.0 in Q3 2023 and bottomed at -$2.5 million in Q2 2026.
• Historically, EBITDA has averaged -$955000.0 across 5 years, with a median of -$812000.0 in 2022.
• The sharpest annual moves came in 2023 and 2026: EBITDA jumped 40.98% in 2023, then sank 293.87% in 2026.
• Over 5 years, EBITDA stood at -$781000.0 in 2022, then plunged by 56.08% to -$1.2 million in 2023, then jumped by 31.01% to -$841000.0 in 2024, then sank by 44.35% to -$1.2 million in 2025, then sank by 106.34% to -$2.5 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$2.5 million, -$1.2 million, and -$725000.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.